用于治疗再狭窄的血小板衍生生长因子受体激酶抑制剂。
PDGF receptor kinase inhibitors for the treatment of restenosis.
作者信息
Levitzki Alexander
机构信息
Unit of Cellular Signaling, Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 91904, Israel.
出版信息
Cardiovasc Res. 2005 Feb 15;65(3):581-6. doi: 10.1016/j.cardiores.2004.08.008.
The clogging of arteries by neointima is a hallmark of atherosclerosis and of restenosis following balloon angioplasty. The realization in the 1980s that PDGF and its receptor play a key role in the onset of neointimal formation led us to develop PDGFR kinase inhibitors as antirestenosis agents. In this review, we describe the development of these inhibitors and their implementation as antirestenosis agents by localized delivery to the site of injury.
新生内膜导致的动脉堵塞是动脉粥样硬化和球囊血管成形术后再狭窄的一个标志。20世纪80年代认识到血小板衍生生长因子（PDGF）及其受体在新生内膜形成起始过程中起关键作用，促使我们开发PDGFR激酶抑制剂作为抗再狭窄药物。在本综述中，我们描述了这些抑制剂的研发情况以及通过局部递送至损伤部位将其用作抗再狭窄药物的应用情况。
Zotero 插件